HGH Fragment 176-191 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

HGH Fragment 176-191

Also known as: AOD9604, hGH 176-191, GH fragment 176-191

Growth hormone (GH) C-terminal fragment / synthetic peptide

Research chemicalLast updated: October 19, 2026Based on 3 peer-reviewed studies

What it is

HGH Fragment 176-191 is a fragment of growth hormone that people use for fat loss, believed to retain the fat-burning properties of GH without affecting blood sugar. Evidence from animal studies is modest; human research is very limited. Not FDA-approved; gray-market research compound; regulatory status unverified.

The scientific side

HGH Fragment 176-191 corresponds to amino acids 176–191 of the C-terminal region of human growth hormone. Early animal research (1978) demonstrated that synthetic peptides spanning this region (including 172–191, 176–191, 177–191, and 178–191) produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin in normal rats, and reduced insulin sensitivity in intravenous insulin tolerance tests at a single dose of 5 nmol/kg body weight. The peptide must contain a minimum informational sequence (at least through amino acid 178) in correct physical configuration to be biologically active — fragments 179–191 and 180–191 were inert. In vitro research has explored the peptide's binding affinity to breast cancer-associated receptor proteins, suggesting potential for enhancing doxorubicin binding to tumor targets when co-loaded in chitosan nanoparticles. The peptide is also categorized in recent reviews as a GH fragment (alias AOD9604) used in online self-administration protocols purportedly to modulate the GH-IGF-1 axis.

Class: Growth hormone (GH) C-terminal fragment / synthetic peptide

Administration & storage

Administration
In vivo administration in rats (route not explicitly specified in abstract) (PMID: 645904)Intracellular/in vitro delivery via chitosan nanoparticles in MCF-7 cell line experiments (PMID: 35783198)
Storage
No storage conditions for HGH Fragment 176-191 are described in any of the reviewed abstracts.
Cautions
Animal data (rat) indicate that hGH 176-191 reduced insulin sensitivity at a single dose of 5 nmol/kg; potential dysglycemic effects in humans are unknown.,A recent narrative review flags this compound (AOD9604) among peptides associated with endocrine and metabolic disturbances, fluid retention, musculoskeletal symptoms, and injection-site reactions when used in unregulated self-administration contexts.,No regulatory approval exists for physique- or performance-related indications; product composition, dose, and purity in unregulated supply chains are uncertain.,Biologically plausible but unproven mitogenic concerns have been raised for GH-axis modulating peptides as a class.,Sterile technique is essential for any injectable compound to prevent infection — this is a universal self-evident caution not specific to this peptide.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification